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ABSTRACT
Background: Financial analysis (budget impact analysis,
BIA) is increasingly required by decision-makers to ascer-
tain the macroeconomic consequences of new product
reimbursement in addition to proof of cost-effectiveness.
Poland is in the process of drafting country-speciﬁc guide-
lines for BIA, positioned as complementary to economic
evaluation in decision-making
Objectives: The aim of this article is to present the Polish
project and compare it with currently available guidance.
Methods: A checklist was developed that focuses on
issues that are unique to BIA. An analysis of the differ-
ences between different national guidelines and their
Polish counterparts was subsequently undertaken.
Results: The Polish project of BIA guidelines is composed
of two sections. The ﬁrst section presents the objective,
the use of BIA, the responsibility for the preparation, and
the target audience. The second section presents impor-
tant methodological aspects that researchers should keep
in mind when carrying out BIA. In comparison to existing
guidance the Polish project appears to be more detailed. It
includes more precise recommendations on perspective,
time horizon, and reliability of data sources; reporting of
results; rates of adoption of new therapies; and the prob-
ability of redeploying resources.
Conclusions: Although there is an increased demand for
BIA, there is only limited guidance on how such studies
should be undertaken. It is hoped that the Polish guide-
lines can contribute to the development of such analyses
and deliver beneﬁt for Polish health-care decision-makers
and beyond.
Keywords: ﬁnancial analysis, budget impact analysis.
Introduction
In 1970, Tofﬂer [1] described a world of “Future
Shock,” in which advances in technology outpaced
society’s ability to cope with them. The many result-
ant problems included ethical, economic, and soci-
etal challenges about how to allocate the beneﬁts of
this brave new world of high technology. In the ﬁeld
of health care this challenge brings into sharper
focus the concept of the provision of quality health
care at an affordable cost. The rapid growth of
health-care expenditures, coupled with slowdown
in the growth of the general economy, has led to
increased interest in health-economic and ﬁnancial
evaluation of health-care programs. Both of these
approaches independently inform health-care
decision-makers: the health-economic evaluation,
which demonstrates the cost-effectiveness, or value
for money, of new intervention, may assist the pri-
oritization of interventions, advocating efﬁciency
maximization as a central objective; the ﬁnancial
analysis, budget impact analysis (BIA), which pro-
vides insight into the budget impact of the inclusion
of the new intervention, addresses the issue of
affordability. The cost-effectiveness and affordabil-
ity has been widely labeled as the “fourth and ﬁfth
hurdle” to market, in addition to the traditional
three hurdles of safety, efﬁcacy, and quality, required
for the licensing of new medical technology.
If medical decision-making is going to be based
on economic data, guidance must be forthcoming.
Without it, such decisions run the risk of degener-
ating into ill-informed negotiations based on evi-
dence of a variable quality. For several years a
growing number of countries have developed guide-
lines that outline issues in the design and carrying
out of health-economic studies [2–19]. Unfortu-
nately, although an increasing number of agencies
have recognized the potential for BIA, guidance for
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such analysis has been slow to develop. Existing
guidance are generally limited in detail, unclear, and
variable in terms of deﬁning what constitutes a BIA.
Poland is in the process of drafting country-
speciﬁc guidelines for BIA, positioned as comple-
mentary to health economic evaluation in
decision-making. The aim of this article is to present
the project of Polish guidelines for conducting BIA
and compare it with existing international guid-
ance, highlighting areas of agreement and dissent.
Background
Pharmaceutical pricing and reimbursement in
Poland have been based until recently on the tradi-
tional clinical trial outcomes, efﬁcacy, safety, and
quality parameters, used for registration. The main
response to rising costs over the past decade has
been the introduction of cost-containment policies,
such as reference price system, based on classiﬁca-
tion of pharmaceuticals into groups of interchange-
able drugs and setting the ﬁxed refund price
according to the lowest priced drug in the cluster.
At the end 2001, Poland implemented the new
Pricing Law [20] to improve the functionality of the
existing pricing and reimbursement system and to
bring Poland into line with the EU’s Transparency
Directive. In this regulation, requirements for justi-
ﬁcation of the proposed price and description of
impact of the drug on direct treatment costs are
speciﬁed [20]. The ﬁrst one can be interpreted as the
ﬁrst step toward taking advantage of health eco-
nomic evaluation the second one addresses the
problem of affordability. The lack of clear inter-
pretation and the lack of suggestions about
approaches/calculations as part of legal framework
raised issues in both ﬁlling out and evaluation of
applications submitted for reimbursement. In an
attempt to bridge this gap, proposals for guidelines
for conducting health economic evaluation and
guidelines for conducting BIA have been prepared
by representatives of academy and government. The
Polish projects, after consultation with interna-
tional experts, were published in a Polish profes-
sional pharmacoeconomic journal [21,22],
presented on Web sites (http://www.farmakoe-
konomika.edu.pl and http://www.decyzjemedyc-
zne.org.pl) and during Polish and international
meetings. Polish Society for Medical Decision Mak-
ing, the professional association for physicians, ini-
tiated consultation with representatives from all
medical faculties, the Polish Medical Chamber,
associations of health care managers, and associa-
tions of local and international manufacturers.
The aim of the projects is to stimulate the provi-
sion of standardized, reliable, and good quality
information for target audience—policy makers and
purchasers of health care services. Among other
things, the guidelines recognize the obstacle and dif-
ﬁculties in conducting health economic and budget
impact studies and the lack of available data and by
serving as reference material stimulate the develop-
ment in accordance with the worldwide trend
toward economic system of reimbursement.
Positioning of  BIA in Relation to Health 
Economic Analysis
BIA should be positioned as complementary to
health economic evaluation and viewed as working
in parallel [23]. The health economic analysis eval-
uates, from the societal perspective, the possible
inclusion of a drug in light of the criterion of cost-
effectiveness after determining the therapeutic
added value. The ﬁnancial analysis looks at the
budgetary macroconsequences on the possible
inclusion of the drug. Insight into these budgetary
consequences was necessary in making the choice
within the unavoidable budgetary restrictions. The
two methods might work together by ﬁrstly identi-
fying cost-effective drugs, then by assessing poten-
tial budget impact of the possible inclusion of a
drug or by reversing this sequence and carrying out
the ﬁnancial analysis ﬁrst so there and then it could
be immediately determined whether there was a suf-
ﬁcient budget available for reimbursement.
The Reason for Special Guidelines for Conducting BIA
The need for carrying out the ﬁnancial analysis has
been mentioned in Appendix 1 of the project of
Polish guidelines for conducting health economic
evaluations, but since the health economic guide-
lines themselves deal purely with the scientiﬁc
methodology of health economic research, it was
believed that the recommendations regarding ﬁnan-
cial analysis should be treated as separate guide-
lines. This arrangement does not imply any
difference in the relative importance of the two
analyses, but was chosen to accentuate the differ-
ence between the two analyses and to stress that
ﬁnancial analysis should not be regarded as a vari-
ant of the health economic analysis conducted from
a purchaser perspective. Admittedly both of them
may share many of the same data, but they differ in
their scope and reporting of the results.
The main advantage of special guidelines for
carrying out ﬁnancial analysis is to establish prin-
ciples for best practice in designing and imple-
menting ﬁnancial analysis. For the ﬁnancial
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analysis, data on the following will be required:
descriptive epidemiology, data on incidence and
prevalence, the patient group that is indicated for
the drug and the anticipated substitution effects,
the use of the drug, its price, and total treatment
costs. This ensures that the ﬁnancial analysis is
based on incidence and prevalence statistics for
the disease rather than on costs per “treatment/
patient.” It is vital to deﬁne accurately, scrutinize
carefully, and reﬁne this type of analysis when
the Committee of Drug Management takes into
account among other criteria “the inﬂuence on
direct costs of treatment” in accordance with the
new Polish Pricing Law.
Information Covered by the Project of  Polish Guidelines 
for Conducting BIA
The present project of guidelines is composed of
two sections. The ﬁrst section presents the objec-
tive, the use of BIA, the responsibility for the prep-
aration, and the target audience. The second section
presents important methodological aspects that
researchers ought to keep in mind when carrying
out BIA. The full version of the project is available
on the Internet (http://www.decyzjemedyczne.org.
pl) and is summarized in Table 1. We will focus here
on some aspects that might be important in the
interpretation and implementation of guidelines for
the parties involved.
Table 1 Information covered by Polish guidelines for BIA (ﬁnancial analysis)
Objective The impact of  the decision on the reimbursement of  a given drug on:
The health-care budget for drugs;
The health-care budget (as total).
Use and status BIA must be performed on all pharmaceutical products for which an application for reimbursement is 
submitted, except: 1) pharmaceutical products with the same active ingredient as in a pharmaceutical 
product for which reimbursement has already been granted, including generic pharmaceuticals, 
parallel-imported preparations, and preparations in new packaging; and 2) pharmaceutical products for 
which a new formulation quite clearly does not change the costs and health effects of  treatment.
Responsibility for the preparation Reimbursement applicant.
Target audience Minister of  Health.
Methodology
General remarks
Transparency BIA should be transparent and allow for understanding of  all input assumptions and relations between 
the variables used in the analyses and the resulting outcomes data on a pharmaceutical agent and its use.
Data sources Key data for the BIA (e.g., epidemiological data, data on resource use, and unit costs; therapy probably 
replaced by new drug; target population) should be country-speciﬁc. The selection of  unit costs attached 
to resource use data should be consistent with the study perspective. The data on the inﬂuence of  new 
therapy on mortality, progression of  disease, events rates (e.g., side effects) may come from various 
sources, not necessarily country-speciﬁc, but must ﬁrst be “translated” to the Polish situation. Relevant 
data should be searched, appraised, and presented according to the principles and methods of  evidence-
based medicine and systematic review. The selection of  sources used should be justiﬁed.
Perspective Public purchaser.
Time horizon Annual ﬁnancial implications to the health-care budget (for drugs as well total) until the proposed drug 
is predicted to have achieved a peak or stable market share or for at least 2 years after the date of  listing 
on the reimbursement list.
Target population Population deﬁned based on the approved indication and also subgroups deﬁned on the basis on potential 
differences in efﬁcacy, costs, and/or preferences.
Presentation of  results Monetary and natural units and impact on service.
Probability of  redeploying
resources
Models used in the BIA should predict the probability of  redeploying any labor or capital savings to other 
areas of  care and predict how the savings will be realized in time.
Sensitivity analysis At a minimum one-way sensitivity analyses to determine where uncertainty or lack of  agreement about
some key-parameter’s value or the functional form of  the model could have a substantial impact on 
conclusion. Inputs such as diffusion rate and probability of  redeploying resources should be varied in any 
interactive model.
Detailed remarks Data on a pharmaceutical agent and its use.
Estimation of  the use of  the proposed drug and other drugs, which are prescribed as a part of  the 
treatment of  the drug suggested for reimbursement or will probably be used less often in the target 
population after placing the drug on the reimbursed drugs list because of  therapeutic indications and side 
effects of  the current treatment.
Formulas for estimation of  the impact of  the decision on the reimbursement of  a given drug on the 
health-care budget for drugs and the health-care budget (as total).
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Objective, Use of  Pharmacoeconomic Analyses, 
Responsibility for Carrying on the Study, and Target 
Audience
The ﬁrst target in the process of implementation
of budget impact arguments into rational decision-
making in Poland are pharmaceuticals because
although their share in total health-care expenditure
is relatively low, they come under speciﬁc legal reg-
ulations [20]. The aim of BIA is to measure the
impact of the reimbursement decision of a given
drug on the budget for drugs and the health-care
budget overall.
BIA must be performed on all pharmaceutical
products for which an application for reimburse-
ment is submitted, except: 1) pharmaceutical prod-
ucts with the same active ingredient as in a
pharmaceutical products for which reimbursement
has already been granted, including generic phar-
maceuticals, parallel-imported preparations and
preparations in new packaging; and 2) pharmaceu-
tical products for which a new formulation quite
clearly does not change the costs and health effects
of treatment. BIA is especially useful for decision-
making concerning pharmaceutical products with
earlier not reimbursed indications or belonging to a
new therapeutic class of products, which were not
reimbursed earlier. This suggests a particular role
for BIA in the reimbursement of new products with
an anticipated therapeutic added value compared
with existing treatments. Argumentation raised
from this evaluation is important, however, it is not
the only element in the complex decision-making
process.
Responsibility for the preparation, ﬁnancing,
and carrying out of BIA rests with the reimburse-
ment applicants, because they are obliged to sub-
mit information requested by Committee of Drug
Management within Ministry of Health. In this
context it is important to emphasize the role of
guidelines, which provide clear instructions on
how these studies must be carried out and ensure
research is performed correctly. The primary target
of BIA is the Minister of Health, who decides
whether the drug will be included in the reimburse-
ment list.
Methodology
Methodological guidelines have been classiﬁed into
general and detailed remarks. General remarks raise
a series of issues that should be considered and
addressed in developing a BIA; detailed remarks
specify what data must be submitted and which
method best ensures comparison between such eval-
uations and also signiﬁcantly reduce the possibility
of misleading conclusions.
General Remarks
Transparency. BIA should be transparent and allow
for understanding of all input assumptions and rela-
tions between the variables used in the analyses
and the resulting outcomes. The predictive model
should be made as interactive as possible. It
improves the credibility of the research, especially in
the case when responsibility for preparation, ﬁnanc-
ing, and carrying out of BIA has been shifted to the
sponsor of a new drug. Accessibility of the model
allows the decision-makers to assess the scenarios
and to undertake their own sensitivity analysis.
Data sources. The source of all data, as well as
additional assumptions made in the absence of
“real” data, should be clearly stated. Key data for
the  BIA,  for  example,  epidemiological  data,  data
on resource use and unit costs, therapy probably
replaced by new drug, and target population,
should be country-speciﬁc. The selection of unit
costs attached to resource use data should be con-
sistent with the study perspective. The data on the
inﬂuence of new therapy on mortality, progression
of disease and events rates, for example, side effects,
may come from various sources, not necessarily
country-speciﬁc, but must ﬁrst be “translated” to
the Polish situation. Relevant data should be
searched, appraised, and presented according to the
principles and methods of evidence-based medicine
and systematic review. The selection of sources used
should be justiﬁed.
When resources are measured in a clinical trial it
is important to distinguish between resources used
in routine practice and those used only in the clin-
ical trial setting. Protocol-driven costs should be
excluded from analysis.
Decision-makers must accept that assumptions
will inevitably be involved in predicting the rate of
adoption of the new therapy before it has been
introduced into the health service. Manufacturers
should provide the basic information: volume of
supplies in the period preceding the submission of
the application and declared for the future, struc-
ture, and volume of sales in Poland.
Perspective. As the objective of BIA is to measure
the impact of the reimbursement decision of a given
drug on the health-care budget for drugs and the
health-care budget overall, the study perspective
should be that of the public purchaser—the key
audience for such analyses. Given that society as
a whole, through contributions, is responsible for
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providing much of the public ﬁnance used in health-
care purchasing, productivity costs, if they are
signiﬁcant, or unpaid caregivers costs could be
included in BIA, provided that the relevance of non-
health-care costs and beneﬁts to the public purchas-
ing bodies is considered. In most cases public health
service purchasers have little opportunity to take
any advantage of gains in nonhealth settings or even
beyond their own department. Consequently, owing
to our inability to transfer savings from beyond the
health-care service, the societal approach is not suit-
able for BIA.
Time horizon. Time horizon of BIA will be inﬂu-
enced by the interest and needs of the target audi-
ence, the therapy under investigation, the nature of
beneﬁts accrued, and the diffusion rate of the new
therapy.  Ideally,  time  horizon  for  the  BIA  should
be until the proposed drug is predicted to have
achieved a peak or stable market share. According
to the project of Polish guidelines for conducting
BIA, annual ﬁnancial implications to the health-care
budget, for drugs as well as total, to this time hori-
zon or for at least 2 years after the date of listing on
the reimbursement list should be estimated. Because
the diffusion rate is one of the key uncertainties in
attempting to assess the budget impact of new ther-
apy, sensitivity analysis should always include a sen-
sitivity analysis on the diffusion rate.
Target population. The target population for BIA is
deﬁned based on the approved indication(s). If the
drug is to be reimbursed only in the case of some
indications (in Poland, there exists a list of drugs
and medical materials for speciﬁed severe, chronic,
and mental illness), the target population is deﬁned
based on the indications, which are signiﬁcant for
the reimbursement. If based on the difference in
effectiveness, costs, and/or preferences, a subpopu-
lation can be distinguished, smaller than the
population determined by the registered drug indi-
cations; such subpopulation should be isolated and
a ﬁnancial analysis should be conducted for the gen-
eral population as well as for the subpopulation.
Given the resource constraints, evidence emerging
from such subpopulation studies may allow for
introducing narrower restrictions on use of several
new medicines than those speciﬁed in the regulatory
approval.
To meet the needs of health-care decision-maker
it would also be advisable to discuss in BIA the
potential off-label use of the new drug. Although it
is hard to make prediction about this phenomenon,
it is suggested that a justiﬁable baseline assumption
should be included in any analysis along with addi-
tional scenarios to allow for sensitivity analysis.
Although this may introduce some complexity into
predictive modeling, ultimately it should produce
results that are more applicable to health-care
decision-making and can be involved in developing
preventive mechanisms.
Cost assessment. In an attempt to standardize the
costing methods recently, the separate project of
Polish guidelines for costing have been issued, to
supplement previous guidelines for conducting
health economic and BIA evaluation with more pre-
cise information about design, performance, and
assessment of cost calculations and to introduce the
proposal of standard list of costs [24]. Key issues in
relation to BIA will be discussed in more detail.
The approaches to measurement and evaluation
of costs vary along a spectrum of speciﬁcity. The
selection of methodology depends on the aim and
the speciﬁc setting of the study and should be made
by the researcher. Nevertheless, the choice of a
speciﬁc methodology should follow standard
recommendations.
Microcosting and gross-costing can be used
within a single analysis. In general, microcosting
will be more important for aspects of the alterna-
tives under consideration that are likely to diverge
in cost; gross-costing is acceptable when using a
more exact microcost estimate cost that will not sig-
niﬁcantly affect the analysis. The identiﬁcation of
units of resources used raises two questions: what
types of resource use are relevant for the disease or
intervention studied and to what level of detail do
they have to be measured and valued separately?
The costs in BIA should be estimated in terms of
the payments actually made or the savings actually
realized by the public purchaser. These involve
different unit prices from those recommended in
health-care evaluation, which reﬂect the opportu-
nity cost rather than charges or tariffs. Conse-
quently, tariffs and other prices in the health-care
sector are applied. The use of standard unit costs
results in the decrease of differences in unit costs
estimates between studies and is recommended in
the case of formal appraisal studies for reimburse-
ment purposes. For the units with the largest con-
tribution to total or incremental costs, however, a
more detailed costing approach might still be nec-
essary, that is, direct calculation of unit costs.
Results should be reported both in natural and in
monetary units. This helps decision-makers to judge
whether reduced natural units of resources, for
example, hospital beds or nursing time, are possible
to redeploy to other areas of care and hence mon-
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etary savings could be realized. In some cases, the
quantitative impact of the new intervention on the
budget may even be of a secondary importance to
the impact on the current use of resources such as
general practitioner consultations and nursing care.
The probability of redeploying resources is an
issue that deserves special attention. Many interven-
tions will have an impact on health-care service use,
reduction in surgery, bed days, consultations, etc.,
and although it is desirable to emphasize this fact to
show the “value” of the treatment, it must be bal-
anced with the sphere of interest of decision-
makers: whether or not real saving is accrued.
Therefore, if possible, the models used in the BIA
should predict the probability of redeploying any
labor or capital savings to other areas of care and
predict how the savings will be realized in time.
Decision-makers must accept that assumptions will
inevitably be involved in predicting the probability
of redeploying resources and should be willing to
discuss the validity of these assumptions.
Depending on the nature of the new intervention,
it might be important to describe the preconditions
of its effective introduction, for example, the need
for training of medical staff, development of new
clinical guidelines, diagnostic facilities, etc. Finan-
cial requirements for these preconditions should be
summarized.
Sensitivity analysis. The impact of uncertain factors
on ﬁnal results should be tested using sensitivity
analysis. Two major sources of uncertainty are dis-
tinguished: parameter uncertainty, uncertainty
about the true numerical values of the parameters
used as inputs, and model uncertainty, model struc-
ture uncertainty, and modeling process uncertainty.
At a minimum, the analyst should conduct one-way
sensitivity analyses to determine where uncertainty
or lack of agreement about some key parameter’s
value or the functional form of the model could
have a substantial impact on conclusion. Further-
more the analyst should conduct multiway sensitiv-
ity analyses for important parameters. Where
parameter uncertainty is a major concern, a plausi-
ble range should be estimated, for example,
extreme values of each key variable in the analysis,
clinically meaningful range, and 95% conﬁdence
interval. Alternatively the analyst varies the param-
eter over a range to determine at what values of the
parameter major changes in conclusion are war-
ranted. When there is substantial uncertainty other
than parameter uncertainty, the analyst may need
to use simulation in a substantially more sophisti-
cated way.
As previously mentioned, because there is likely
to be signiﬁcant uncertainty around the inputs, for
example, diffusion rate and probability of redeploy-
ing resources, it would be wise to allow for them to
be varied in any interactive model.
Detailed Remarks
Data on a pharmaceutical agent and its use. The
BIA must include data on the preparation’s name,
ATC (anatomic, therapeutic, chemical) classiﬁca-
tion, and date of approval for use in Poland; include
information of efﬁcacy and safety; and be based on
the accepted supplementary protection certiﬁcate
(SPC). It must specify in the indication’s description
whether the indication in its entirety or only parts of
the indication is or are most relevant for reimburse-
ment and which parts of the indication the analysis
concerns. It must describe daily doses and expected
treatment period, as well as anticipated frequency
of repetition of treatments, if relevant. It should
state which others drugs or forms of medical treat-
ment could be expected to be used concomitantly. If
the treatment is expected to result in a reduction in
the use of other drugs or additional therapy, this
should be speciﬁed and reasons should be given.
The names of drugs that, after inclusion of sug-
gested drug on the reimbursement list, are likely to
be used less often in the target population because
of therapeutic indications, side effects of the current
therapy, and interactions that will limit or increase
comedication should be indicated.
Estimation of the use of the proposed drug. The
estimated use of the drug to be reimbursed in each
of the ﬁrst 2 years starting from the date of placing
the drug on the reimbursed drugs list should be
included in BIA. The probable number of patients
eligible for the proposed drug, the daily dosage, the
estimated time of treatment, and if necessary, the
frequency of repeating the treatment should be
considered.
The probable number of patients taking a pro-
posed drug and its therapeutic substitutes should be
based on epidemiological data, such as prevalence
and incidence. If treatment is expected to last up to
1 or 2 years, this will be most accurately reﬂected in
the annual incidence of the disease. In the case of
drugs to treat more chronic conditions, estimates of
the prevalence of the disease are more appropriate.
If the extension of survival is expected, it may be
necessary to consider the increase of the prevalence
of a given illness.
The expected number of patients for each of
the suggested indications for the reimbursement
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should be estimated separately and these esti-
mates should be summed. These data are the basis
for the estimate of the likely prescription volumes
of the proposed drug at least during each of the
ﬁrst 2 years from the date of placing the drug
on the list of reimbursed drugs. These estimates
should then be modiﬁed to establish the likely
market share of the proposed drug. The main fac-
tors, which should be considered in this case, are
the substitution of other drugs and the induced
demand.
The  estimation of the use of other drugs. The
changes in the extent of use of other drugs, which
result from placing the drug on the reimbursed
drugs list, should be estimated in the BIA. This per-
tains to drugs which: 1) are prescribed as a part of
the treatment of the drug suggested for reimburse-
ment and 2) will probably be used less often in the
target population after placing the drug on the
reimbursed drugs list because of therapeutic indica-
tions, side effects of the current treatment, and
interactions.
The estimate of the usage of the above-
mentioned drugs should be calculated according to
the method described in estimation in the use of the
proposed drug.
Estimation of the impact of the decision on the
reimbursement of a given drug on the health-care
budget for drugs. The ﬁnancial implication of the
decision to reimburse a given drug for the health-
care budget for drugs can be expressed using the
formula
(il ¥ sl) - (Srk ¥ sk) + (Siw ¥ sw) - (Srn ¥ sn), (1)
where l is the drug proposed for reimbursement, il is
the expected sales (number of units) of drug l, sl is
the subvention of the drug l unit from the health-
care budget for the reimbursement of drugs, k is the
competitive drug for drug l, rk is the reduction in use
of drug k resulting from successful reimbursement
of drug l, sk is the subvention of the drug k unit from
the health-care budget for the reimbursement of
drugs, w is the drug coprescribed with drug l, iw is
the estimated use of drug w, sw is the subvention of
the drug w unit from the health-care budget for the
reimbursement of drugs, n is the drug used because
of side effects of drug k, rn is the reduction in use of
drug n, and sn is the subvention of the drug n unit
from the health-care budget for the reimbursement
of drugs.
In the case of each drug up to three different sub-
ventions from the health-care budget may apply
owing to three different levels of patient’s copay-
ment: lump sum, 30%, and 50%, and the binding
limits.
If there is no competitive market for drug l or if
drug l can be substituted by a different nonpharma-
ceutical treatment, it is not taken into consideration
in the analysis of drugs k and n. If the alternative of
drug l is “no treatment,” the consequence of which
is symptomatic treatment with different drugs, these
drugs are described as k. Side effects can be ignored
if clinical trials have shown that they are insigniﬁ-
cant or if they are similar or the same for drugs l and
k. If information from randomized controlled clin-
ical studies is insufﬁcient for determining the inﬂu-
ence of side effects on the health-care budget for
drugs, this should be noted in the analysis. The time
horizon of the analysis should correspond to the
time necessary to obtain a maximum or stable share
in the market of drug l. The 1-year impact of the
reimbursement of drug l on the health-care budget
for drugs during this time horizon or at least during
the ﬁrst 2 years from the date of placing drug l on
the reimbursed drugs list should be estimated. This
analysis should use constant prices, no allowance
for inﬂation, and a 5% discount rate.
Estimation of the impact of the decision on the
reimbursement of a given drug on the health-care
budget (as total). The ﬁnancial implication of the
decision to reimburse a given drug for the health-
care budget can be expressed using the formula
(ll ¥ kl) - (Srlk ¥ kk) - s, (2)
where l is the drug suggested for reimbursement, k
is the competitive treatment method for drug l, l is
the predicted number of patients treated with drug
l, kl is the cost of treatment with drug l covered by
the health-care budget, rlk is the predicted decrease
of the number of patients treated with k, kk is the
cost of treatment with k covered by the health-care
budget, and s is the savings resulting from the
decrease of burden of illness by using drug l (The
treatment  cost  includes  the  acquisition  costs  of
the given drug and the drugs coprescribed with it,
also owing to side effects, the cost of consultations,
hospitalizations, and medical procedures that may
take place while using a given drug.)
The time horizon of the analysis should corre-
spond to the time necessary to obtain a maximum
or stable share in the market of drug l. The annual
ﬁnancial implication of the reimbursement of drug l
on the health-care budget during this time horizon
or at least during the ﬁrst 2 years starting from the
date of placing drug l on the reimbursed drugs list
should be estimated. This analysis should use con-
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stant prices, no allowance for inﬂation, and an
annual discount rate of 5%. The costs should be
estimated based on current payments made and
real ﬁnancial savings obtained by the health-care
budget.
Polish versus Existing Guidance on BIA
Existing guidance on BIA is limited, often unclear
and variable in terms of deﬁning what constitutes
ﬁnancial analysis and how it should be undertaken
[23]. The most detailed guidance on BIA provides
Australian guidelines for the pharmaceutical indus-
try on preparation of submissions to the Pharma-
ceutical Beneﬁts Advisory Committee [4]. These
guidelines specify that submission for reimburse-
ment should “estimate the likely prescription vol-
ume of the proposed drug on the PBS for at least
each of the ﬁrst 2 full years from the date that it is
listed on the Schedule” and “an epidemiological
approach should be adopted to estimate the likely
patient number projected to be eligible for the pro-
posed drug and its comparator.” In addition, any
substitution effects with other reimbursed medica-
tions currently in use should be included, as
should the impact on any other health-care
resources, and special formulas for calculation are
given. The suggested time horizon for the analysis
is 2 years after launch and allows for sensitivity
analysis around the rate of uptake of the therapy.
The long-term effects can be considered although
these may need to be reported separately. The
costs should be estimated in terms of the payments
actually made or the ﬁnancial savings actually
realized by the governments. These involve differ-
ent unit prices than those recommended in health
economic evaluation.
In England and Wales guidance issued by NICE
(National Institute for Clinical Excellence) recom-
mends consideration of the wider NHS implications
that includes: 1) predictions of the proportion of eli-
gible patients who might use the technology, which
facilitates estimation of aggregate costs and bene-
ﬁts; 2) budget impact; and 3) service impact [18].
For new technologies budget impact should include
estimates of the changing budget impact over a 3- to
5-year period as a result of varying diffusion rates
and also an estimate of impact once diffusion has
reached a steady state. This time horizon corre-
sponds with 3- to 5-year funding agreements in the
United Kingdom, announced in 1997 [25]. A simi-
lar approach had been suggested in a Hungarian
proposal for methodologic guidelines for conduct-
ing economic evaluation of health-care intervention
[19].
Dutch guidelines for health economic research
state in addition to incremental costs and beneﬁt,
the submission for reimbursement should “also pro-
vide an insight into total costs and effects of both
treatments under investigation” [16]. The calcula-
tion of the macrobudget effects still needs some
clariﬁcation.
In the other countries the decision-making bodies
have only recognized the need for BIA, but neither
formal nor informal guidance exists. For example,
in France the price is negotiated with the Comitee
Economique des Produits de Sante (CEPS) on the
basis of the Amelioration du Service Medical Rendu
(ASMR) but also incidence/prevalence of the dis-
ease, public health concern, and drug budget to
assess the budgetary impact [26]. In Spain, the
budget impact is also considered during the price
and reimbursing negotiation. The royal decree 271/
1990, which regulates these processes, requires a
forecast of the sales as an element for the ﬁnal deci-
sion [26]. In Italy, new negotiation guidelines issued
in February 2001 require submission of a cost-
effectiveness study, mostly for orphan and innova-
tive drugs; pricing and reimbursement status in
other countries; commitments on volume sales,
discounts to hospital, etc.; payback clauses, price
reductions, or delisting if sales rise above agreed lev-
els; and data on research and manufacturing invest-
ment in Italy [26]. Sales volume and turnover will
be monitored on an annual basis.
For the purposes of the Polish project, the guide-
lines mentioned above have been in some parts spe-
cially adapted and some points have been better
clariﬁed. From Australian guidelines the Polish
project adopts epidemiological approach, time hori-
zon, formulas for calculation, and from NICE
guidelines—the guideline on service impact. The
difference between Polish and other existing guide-
lines lies in the fact that Polish guidelines had been
issued separately, to stress that ﬁnancial analysis
should not be regarded as a variant of the health
economic analysis conducted from a ﬁnancial per-
spective, and more attention had been drawn to
general remarks, as for example, target population,
probability of redeploying resources, the need for
reporting results both in natural and monetary
units, and the need for interactive models.
Practical Implications
The extent to which guidelines for BIA will become
a useful tool for Polish medical decision-makers
remains to be seen. BIA is positioned as complemen-
tary to health economic analysis. Both of them are
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indispensable to provide decision-makers with reli-
able and good quality information. Nevertheless,
both of these can give contradictory messages to
decision-makers, when, for example, the cost-
effectiveness of the drug improves as the number
who beneﬁts increases. Ideally, to make decision-
making process transparent, the weight of health
economic evaluation and the BIA in decision-
making process needs to be deﬁned before formal
requirements can be implemented. This approach
seems to be, however, too pragmatic. In the real
world difﬁcult decisions on health-care rationing
should carefully balance information on cost-
effectiveness, budget impact, and other factors such
as ethical, equity, and other political considerations.
Health-care decision-makers rarely have a single,
clearly deﬁned goal. Nevertheless, the explicit use of
standard BIA guidelines creates a more transparent
resource allocation process and may ultimately
contribute to the development of an economically
viable and sustainable health-care system. Despite
uncertainties in the methodology and lack of expe-
rience in making practical use of ﬁndings, decision-
making supported by reasonable data is superior to
decision-making unsupported by such data.
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